Mangoceuticals, Inc. (MGRX) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.22
↓-90% vs avg
5yr avg: 2.20
30Y Low0.3·High5.8
ROE
↑
-141.7%
↓+75% vs avg
5yr avg: -563.9%
30Y Low-142%·High-118%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MGRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mangoceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $3M | $7M | $5M | $4M | — | — |
| Enterprise Value | $2M | $6M | $5M | $4M | — | — |
| P/E Ratio → | -0.16 | — | — | — | — | — |
| P/S Ratio | 7.30 | 16.34 | 7.78 | 6.09 | — | — |
| P/B Ratio | 0.22 | 0.49 | 0.34 | 5.75 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MGRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.76 | 8.03 | 5.26 | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
MGRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Mangoceuticals, Inc. earns an operating margin of -4200.5%. Operating margins have compressed from -1260.3% to -4200.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -141.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 54.9% | 54.9% | 61.7% | 59.0% | 54.3% | — |
| Operating Margin | -4200.5% | -4200.5% | -1294.4% | -1260.3% | -22279.7% | — |
| Net Profit Margin | -4526.9% | -4526.9% | -1413.6% | -1259.4% | -22352.1% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -141.7% | -141.7% | -118.3% | -1326.7% | -669.0% | — |
| ROA | -131.2% | -131.2% | -106.0% | -897.0% | -389.5% | -78.5% |
| ROIC | -102.2% | -102.2% | -83.8% | -3083.5% | -1051.8% | — |
| ROCE | -131.5% | -131.5% | -107.8% | -1165.2% | -548.7% | — |
MGRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $307823, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.17 | 0.57 | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | 0.01 | -0.79 | -0.54 | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -198.43 | -198.43 | -634.60 | — | -307.68 | -96.80 |
Net cash position: cash ($1M) exceeds total debt ($307823)
MGRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.74x means Mangoceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.88x to 1.74x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | 1.74 | 0.05 | 3.88 | 2.67 | 0.57 |
| Quick Ratio | 1.74 | 1.74 | 0.05 | 3.79 | 2.67 | 0.57 |
| Cash Ratio | 1.67 | 1.67 | 0.04 | 3.50 | 2.62 | 0.57 |
| Asset Turnover | — | 0.03 | 0.04 | 0.70 | 0.01 | — |
| Inventory Turnover | — | — | — | 16.21 | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
MGRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mangoceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 16.7% | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 16.7% | 0.0% | — | — |
| Shares Outstanding | — | $10M | $2M | $1M | $1M | $997666 |
Peer Comparison
Compare MGRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MGRXYou | $3M | -0.2 | — | — | 54.9% | -4200.5% | -141.7% | -102.2% | — |
 HIMS | $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 AMWL | $141M | -1.4 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 TDOC | $1B | -7.1 | 17.1 | 5.1 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 OPRX | $93M | 18.4 | 5.9 | 5.0 | 63.3% | 11.0% | 4.2% | 6.8% | 1.6 |
 WELL | $145B | 148.7 | 64.6 | 50.8 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 NUVB | $2B | -9.3 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 ATAI | $1B | -1.4 | — | — | 75.3% | -2439.7% | -389.9% | -57.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MGRX — Frequently Asked Questions
Quick answers to the most common questions about buying MGRX stock.
What is Mangoceuticals, Inc.'s P/E ratio?
Mangoceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Mangoceuticals, Inc.'s ROE?
Mangoceuticals, Inc.'s return on equity (ROE) is -141.7%. The historical average is -130.0%.
Is MGRX stock overvalued?
Based on historical data, Mangoceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Mangoceuticals, Inc.'s profit margins?
Mangoceuticals, Inc. has 54.9% gross margin and -4200.5% operating margin.